Related Experiment Video
Updated: Jun 11, 2026
09:48
Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Obesity genes and insulin resistance
Anna C Belkina1, Gerald V Denis
1Boston Nutrition Obesity Research Center, Cancer Research Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Current Opinion in Endocrinology, Diabetes, and Obesity
|June 30, 2010
Summary
Obesity increases Type 2 diabetes risk, but some obese individuals are protected. Reduced inflammation in fat, linked to a Brd2 gene mutation, may explain this protection, offering new therapeutic targets for diabetes prevention.
Area of Science:
- Immunology
- Genetics
- Metabolic Diseases
Background:
- Obesity and Type 2 Diabetes (T2D) are rising global health crises.
- Metabolically healthy but obese (MHO) individuals show protection against T2D and cardiovascular risks.
- The molecular mechanisms underlying MHO protection, particularly reduced inflammation, require further investigation.
Purpose of the Study:
- To explore the inflammatory cells and pathways involved in overnutrition-induced metabolic dysfunction.
- To understand the genetic and molecular basis of protection in metabolically healthy but obese individuals.
- To identify potential therapeutic targets for preventing T2D in obese populations.
Main Methods:
- Review of current literature on inflammation, obesity, and insulin resistance.
- Analysis of findings from genetic studies, including the role of the Brd2 gene.
- Comparison of molecular mechanisms in mouse models with human MHO populations.
Main Results:
- A genetic mutation in the Brd2 gene in mice leads to obesity but confers protection against diabetes.
- Brd2-hypomorphic mice exhibit reduced inflammation in adipose tissue, similar to MHO patients.
- These findings suggest a link between Brd2, inflammation, and metabolic health in obesity.
Conclusions:
- Understanding the genetic control of inflammatory responses to diet-induced obesity is critical.
- Targeting inflammatory pathways offers potential therapeutic strategies for obese, insulin-resistant patients.
- Further research into genes like Brd2 could unlock novel treatments for T2D prevention.
More Related Videos
10:40Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
Published on: December 5, 2025
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:36Carbohydrate Metabolism
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...